Duration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelve.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PERSEPHONE
- 14 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 13 Aug 2015 Accrual to date is 102% according to United Kingdom Clinical Research Network record.
- 04 Jul 2015 Accrual to date is 99% according to United Kingdom Clinical Research Network record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History